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Summary Meningiomas are common, mostly benign, tumours arising from leptomeningeal cells of the meninges, which frequently contain
mutations in the neurofibromatosis type 2 (NF2) gene. In this study, we analysed a protein product of the neurofibromatosis type 1 (NF1)
gene, neurofibromin, in human established leptomeningeal cells LTAg2B, in 17 sporadic meningiomas and in a meningioma from a patient
affected by NF2. The expression level of neurofibromin was determined by immunoblotting and immunoprecipitation with anti-neurofibromin
antibodies. The functional status of neurofibromin was analysed through its ability to stimulate the intrinsic GTPase activity of p21 ras. In the
cytosolic extracts of four sporadic meningiomas and in the NF2-related meningioma, the expression level and the GTPase stimulatory activity
of neurofibromin were drastically reduced compared with the level present in the human brain, human established leptomeningeal cells
LTAg2B and the remaining 13 meningiomas. Our results suggest that neurofibromin is expressed in leptomeningeal cells LTAg2B and in most
meningiomas, i.e. tumours derived from these cells. The reduced expression and GTPase stimulatory activity of neurofibromin was found in
about 23% of meningiomas and in the single NF2-related meningioma analysed. These results suggest that decreased levels of
neurofibromin in these tumours may contribute to their tumorigenesis.
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Neurofibromatosis type 1 (NFl) and neurofibromatosis type 2
(NF2) are the two most clearly defined diseases among neuro-
fibromatoses (Mulvihill et al, 1990). The incidence and clinical
expressions ofNFl and NF2 are quite different. While NFl is one
ofthe most common autosomal, dominantly inherited disorders in
humans (incidence 1 in 4000 to 1 in 3000 live births), NF2 is a
very rare condition (incidence 1 in 40 000). Characteristic abnor-
malities in NFl include multiple neurofibromas, skin pigmenta-
tions called cafe au lait spots, axillary freckling, Lisch nodules of
the iris and many other clinical manifestations (Riccardi, 1992).
The hallmark of NF2 is bilateral vestibular schwannomas, i.e.
Schwann-cell tumours that arise from the vestibular branch of the
eighth cranial nerve (Martuza and Eldridge, 1988).
The phylogenetically conserved genes that are targets for NFl
andNF2 reside on different chromosomes (chromosome 17 and 22
respectively) and both have been cloned in theirentirety (Marchuk
et al, 1991; Bemards et al, 1992; Rouleau et al, 1993; Trofatter et
al, 1993). TheNFl gene encodes a 2818 amino acid protein, desig-
nated neurofibromin. A 360 amino acid region of neurofibromin
shows significant homology to the catalytic domain of the
mammalian p21 ras-specific 120-kDa GTPase-activating protein
(p120 GAP), yeast equivalents IRAI and IRA2 proteins and
recently identified mammalian p21 ras-specific GAPs (Ballester et
al, 1990; Maekawa et al, 1994; Weisbach et al, 1994; Baba et al,
1995). This GAP-related domain (GRD) ofneurofibromin, as well
as the full-length neurofibromin, can negatively regulate p21 ras in
Received 29 October 1996
Revised 12 February 1997
Accepted 20 February 1997
Correspondence to: M Golubic, Cleveland Clinic Foundation, Department of
Neurosurgery, 9500 Euclid Avenue/NC2-150, Cleveland, OH 44195, USA
vitro by stimulating its weak intrinsic GTPase activity (Xu et al,
1990; Golubic et al, 1992).
Normal cellular growth in response to peptide growth factors is
dependent on the presence of functional p21 ras molecules in the
cell (Stacey et al, 1991; Lowy and Willumsen, 1993). The biolog-
ical activity of p21 ras is regulated by guanosine triphosphate
(GTP) binding and hydrolysis to guanosine diphosphate (GDP)
(Lowy and Willumsen, 1993). The GTP-bound form of p21 ras is
biologically active, while p21 ras-GDP is inactive. Nearly all acti-
vating point mutations found in ras genes in numerous types of
human tumours (Boss, 1989) decrease intrinsic GTPase activity of
p21 ras and render it insensitive to stimulation by GAPs (Trahey
and McCormick, 1987; Lowy and Willumsen, 1993). The trans-
forming activity of mutant p21 ras is, therefore, considered as the
consequence of p21 ras being constitutively activated in its GTP-
bound state. Thus, loss offunction ofGAPs to negatively regulate
the activity of p21 ras might be important in the tumorigenesis
process. Supporting this idea, mutations of the NFl gene and
reduced neurofibromin expression and catalytic activity were
described in NFl-associated tumours and sporadic tumours of
various types (Li et al, 1992; von Deimling et al, 1995). Decreased
expression of p120 GAP or its shorter placental isoform has been
demonstrated in benign and malignant human trophoblastic
tumours (Stahle-Backdhal et al, 1995).
Meningiomas are tumours derived from leptomeningeal cells,
specifically the arachnoid cap cells surrounding the brain and
spinal cord. These tumours account for up to 20% of all primary
intracranial neoplasms and 25% of intraspinal tumours (Russel
and Rubinstein, 1989). Although meningiomas are usually benign,
they often recur after seemingly complete surgical removal and
occasionally progress to a fully malignant phenotype (Kujas,
1993). Clinically and histologically, meningiomas are a diverse
group of tumours classified into different histological subtypes
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Table 1 Clinical data and neurofibromin expression in sporadic meningiomas
Tumour Age Sex Location Histology IB IP/IB IP/GTPase assay Maltoside
(years) Ratio NF1/GAP sensitivity
1 25 F Frontal fossa Transitional (NF2) R R 0.18 (16.4/88.9) R
2 77 F Spine Meningotheliomatous R R ND +
3 42 F Sphenoid wing Meningotheliomatous + ND ND +
4 36 F Posterior fossa Transitional + ND ND +
5 35 F Petroclival Meningotheliomatous + ND ND +
6 77 F Sphenoid wing Meningotheliomatous R ND ND R
7 48 F Sphenoid wing/infratemporal Transitional R R 0.59(42.4/71.7) R
8 68 F Foramen magnum Meningotheliomatous R R 0.36(18.7/52.1) R
9 70 F Frontoparietal convexity Fibroblastic/psammoma bodies + + 1.27 (97.1/76.5) +
10 69 M Tuberculum sella Transitional + + ND ND
11 46 F Sphenoid wing Meningotheliomatous + + 1.2 (79.5/66.2) +
12 41 M Frontoparietal convexity Malignant + + 1.26 (79.0/62.8) +
13 61 F Tentorial Meningotheliomatous/secretory + + 0.93 (81.2/86.8) +
14 74 F Parasagittal Malignant R R 0.56 (26.8/48.0) R
15 68 F Spinal Meningotheliomatous/psammoma bodies + + 0.99 (75.2/75.3) +
16 67 F Occipital convexity Transitional/infiltrating + + 1.23 (88.1/71.6) +
17 54 F Parietal/occipital convexity Malignant + + 1.19 (77.8/65.2) +
18 48 F Petrous Meningotheliomatous + R 0.63 (37.8/59.7) +
HB + + 1.00 (100.0/100.0) +
IB, immunoblotting of neurofibromin; +, intensity of neurofibromin 250-kDa band is similar to brain tissue and established leptomeningeal cells LTAg2B; R,
intensity of neurofibromin 250-kDa band is reduced in comparison with brain tissue and established leptomeningeal cells LTAg2B; IP/IB, neurofibromin
immunoprecipitation by anti-NF1 (Cl) serum followed by immunoblotting; IP/GTPase assay, neurofibromin immunoprecipitation followed by p21 ras
immunoprecipitation GTPase assay; NF1, neurofibromin; GAP, p120 GAP; ratio NFl/GAP, percentage of GTPase activity of NF1 compared with human brain
divided by the percentage of GTPase activity of p120 GAP compared with human brain (shown in brackets); HB, human brain; ND, experiment not done.
Maltoside sensitivity: +, sensitivity is similar to that of the brain tissue; R, reduced sensitivity. The results different from normal are italicized.
(Scheithauer, 1990). Little, however, is known about the molecular
mechanisms responsible for the development and histopatholog-
ical heterogeneity ofthese tumours (Collins, 1990).
The NF2 gene seems to be the major meningioma gene because
of its frequent mutational inactivation in sporadic meningiomas
(Lutchman and Rouleau, 1996). The levels of the NF2 protein,
termed schwannomin (Rouleau et al, 1993) or merlin (Trofatter et
al, 1993), are severely reduced in almost 60% of sporadic menin-
giomas, as demonstrated in our recent analysis (Lee et al, 1997).
Besides the NF2 gene, several candidate meningioma genes were
identified (Murphy et al, 1993; Peyrard et al, 1994; Lekanne
Deprez et al, 1995).
The possibility that the NFl gene plays a role in meningioma
development has not been explored experimentally. Such plausi-
bility, however, is supported by at least two observations. Firstly,
some pathological features of NFl and loss of control of cell
growth are apparent in neural crest-derived tissues (Basu et al,
1992; DeClue et al, 1992), and meninges are thought to be partly
of mesenchymal and partly of neural crest origin (O'Rahilly and
Mueller, 1986). Secondly, the involvement of NFI gene-bearing
chromosome 17 in meningioma development is suggested by
some cytogenetic studies (Yamada et al, 1980; Maltby et al, 1988).
Mutational analysis of the NFl gene is complicated by its large
size, numerous exons and the presence of pseudogenes (Li et al,
1995). At least 80% of the identified mutations potentially encode
truncated proteins because of premature translation termination
(Heim et al, 1994; von Deimling et al, 1995). As such, the analysis
of neurofibromin by specific antibodies could reveal the conse-
quences ofmost NFl mutations either by the presence oftruncated
proteins or by reduced expression of the full-length neuro-
fibromin. The biochemical analysis of GAP activity of tumour-
derived neurofibromin could be used to determine effects of
mutations that might occur in the GRD ofthe protein. The analysis
of protein has an additional advantage. In contrast to the ubiqui-
tous expression of the NFl gene, neurofibromin is predominantly
expressed in the adult brain (Daston et al, 1992; Golubic et al,
1992). Therefore, neurofibromin derived from non-tumorous cells
present in the tumour, such as lymphocytes, macrophages,
endothelial cells, etc., would have only minor significance in the
interpretation of the results.
In this study, we determined first the expression level of
neurofibromin in established human leptomeningeal cells,
LTAg2B, using immunoblotting experiments with two specific
antibodies. Then, to test the hypothesis that the loss of function
of neurofibromin is involved in meningioma development, we
determined the expression levels and the GAP activity of neuro-
fibromin upon p21 ras in one NF2-related meningioma and in
17 primary sporadic meningiomas.
PATIENTS AND METHODS
Tissue samples and cell lines
Human brain and tumour tissue specimens were obtained form the
operating room with the patient's consent and approval of the
Institutional Review Board (Cleveland Clinic Foundation IRB no.
5400). The NF2 patient, a 25-year-old woman, participating in this
study met the criteria agreed upon in a consensus conference at the
National Institutes of Health (Mulvihill et al, 1990). She presented
with bilateral vestibular schwannomas and multiple intracranial
meningiomas. Normal brain specimen was obtained from an epilepsy
patient with no apparent structural lesion and who was undergoing
temporal lobectomy. Diagnosis ofmeningiomas and theirhistopatho-
logical classification was determined by neuropathologists.
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Figure 1 Immunoblotting of soluble protein fraction of human brain tissue
(HB), established human leptomeningeal cells LTAg2B (LTAg2B), murine
fibroblast cells NIH3T3 (NIH) and the human astrocytoma CRT cell line
(CRT) by anti-NF1GRP(N) IgG (top) and anti-p120 GAP IgG (bottom), as
described in the Patients and methods section. The protein amount in
micrograms (gg) that was analysed is indicated above the upper panel.
Molecular size standards in kDa are indicated on the right. On the left, NF1
indicates neurofibromin band, while GAP indicates p120 GAP-specific band
The leptomeningeal cell line LTAg2B was established from a
primary culture ofhuman leptomeningeal cells transfected with an
SV40 T antigen construct (Murphy et al, 1991). The cells were
grown in minimum essential medium with Earle's salts (Gibco
BRL) supplemented with 10% fetal calf serum and
antibiotic-antimycotic agents. Murine fibroblast cells NIH 3T3
were grown in Dulbecco's modified eagle medium (DMEM)
(Gibco BRL) supplemented with 10% calf serum and 1% peni-
cillin/streptomycin. Human astrocytoma (CRT) cells, isolated
from a grade IV glioblastoma, were grown in DMEM with 10%
fetal calf serum (Estes et al, 1990).
kDa
Preparation of tissue extracts
Immediately upon surgical excision tumour or normal human
brain tissue was transported on ice to the laboratory in buffer A
(50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM DTT and a cocktail
of protease inhibitors). Tumour tissue was homogenized using a
Polytron PT 3000 (Brinkmann) in buffer A. The homogenate was
centrifuged at 100 000 g for 60 min, and the supernatant
containing the cytosolic, soluble proteins (S100 fraction) and
pellet was saved. The pellet was briefly homogenized, washed
twice with buffer A and resuspended in buffer A containing 1%
Triton X-100. After a 30-min incubation on ice, the sample was
centrifuged at 100 000 g for 60min at 4°C. Supernatant (1%
Triton fraction) was saved and stored in aliquots along with SI00
fraction in an -850C freezer. The protein concentration of the
tumour samples was determined using BCA protein assay reagent
from Pierce, according to the protocol specified by the manufac-
turer, with a bovine serum albumin (BSA) standard.
LTAg2B, NIH3T3 and CRT cells were grown to confluence,
washed three times in ice-cold phosphate-buffered saline (PBS)
and scraped off the plates in buffer A. Cell lysates were prepared
by sonication (3 x 10 s, 35% output) in a sonic dismembrator
(Fisher, Model 300). All subsequent steps were performed as
described above for brain and meningioma tissue samples.
Immunoblotting of neurofibromin and p120 GAP
Total proteins from prepared fractions of the tumour lysates and
positive control tissue were separated using standard 7% sodium
dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis
(SDS/PAGE) on a Bio-Rad Protean 11 16-cm cell. As a positive
control, Sl00 fraction of rabbit and human brain was used, as the
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Figure 2 Immunoblotting of soluble fraction of 18 meningiomas. A 100-gg aliquot of soluble fraction of human brain (HB) and 18 meningiomas (nos. 1-18, see
Table 1) was immunoblotted with (A) anti-NFl GRP(N) IgG, (B) anti-NF1GRP(D) IgG, (C) anti-p120 GAP IgG and (D) anti-actin IgG. Molecular size standards in
kDa are indicated on the left. On the right, NF1(N) indicates neurofibromin recognized by anti-NF1GRP(N) IgG, NF1(C) indicates neurofibromin detected by anti-NFlGRP(D) IgG, and GAP stands for p120 GAP-specific band. Tumour samples nos. 13-18 are from a different gel, with longer exposure in the case of
anti-NFlGRP(N) IgG and anti-actin immunoblotting
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Figure 3 Detection of neurofibromin by immunoprecipitation followed by immunoblotting. (A) Neurofibromin (marked NF1 on the right) was
immunoprecipitated from 4 mg of soluble fraction of rabbit brain (RB) and meningiomas (tumour number is indicated below) by anti-NF1GRP(N) IgG (marked as
N above the gel) or anti-NF1GRP(D) IgG (marked as C above) and immunoblotted with anti-NF1GRP(N) IgG. The first lane in which non-immune serum was
used for immunoprecipitation is indicated by non-imm. above. Immunoprecipitation reactions with only 1 mg of protein are indicated by an asterisk. (B)
Immunoprecipitation analysis of NF2-related meningioma (tumour no. 1). In lanes 2, 4, 6 and 8, immunoprecipitation was performed with the non-immune
serum. In lanes 1 and 3, immunoprecipitation was performed with anti-NF1(Cl) serum and in lanes 5 and 7 with polyclonal anti-pl20 GAP IgG. A total of 4 mg
of NF2-related meningioma (lanes 1, 2, 5 and 6) and rabbit brain (lanes 3, 4, 7 and 8) as a positive control were used. Immunoblotting of immunoprecipitated
proteins was performed with anti-NF1(Cl) serum (lanes 1-4) and anti-p120 GAP IgG (lanes 5-8). (C) Immunoprecipitation analysis of meningioma no. 2 lysate.
Immunoprecipitation was performed by non-immune serum (lane 1) and by anti-NF1(Cl) serum from 1 mg of soluble protein from rabbit brain (lane 2) and
meningioma no. 2 (lane 3). Immunoblotting was done with anti-NF1(Cl) serum. NF1 indicates the neurofibromin-specific band. (D) Immunoprecipitation was
performed by anti-NFlGRP(N) IgG (indicated by N above) and anti-NF1(ClI) serum (indicated by C above) from 2 mg of protein of rabbit brain (RB). A total of
2 mg of protein from meningiomas, with tumour number indicated at the bottom of the figure, was immunoprecipitated with anti-NF1(Cl) serum (top) or with
anti-p120 GAP IgG (bottom). Neurofibromin and p120 GAP immunoprecipitates were first used to measure their GTPase stimulatory activity and then boiled in
Laemmli buffer followed by SDS/PAGE. Immunoblotting was done using anti-NF1(Cl) serum (top) and anti-p120 GAP (bottom)
non-tumorous tissue from the patients was not available. The
protein samples were run along with prestained protein standards
and transferred by a semi-dry transfer cell (Trans-blot SD, Bio-
Rad) to supported nitrocellulose membrane (Schleicher & Schuell)
in buffer containing 48 mm Tris, 39 mM glycine, 0.0375% SDS and
20% methanol, pH 9.2. The nitrocellulose filters were incubated in
blocking solution (5% dry milk, 10 mm Tris-HCl, pH 8.0, 150 mM
sodium chloride, 0.05% T\veen 20) for 1 h at room temperature.
Two commercially available polyclonal anti-neurofibromin anti-
bodies (Santa Cruz Biotechnology) raised in rabbits against two
peptides were diluted in blocking buffer to the final concentration
of 0.25 gg ml-'. The first anti-neurofibromin antibody designated
anti-NFIGRP(N) IgG recognizes an epitope localized at the amino
terminus of the human neurofibromin (amino acid residues
509-528), while anti-NFlGRP(D) antibody is specific for the
epitope at the carboxy terminus (residues 2798-2818) of human
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Figure 4 Analysis of total (grey bars) and maHtoside-inhibited GAP activity
(solid bars) ofsoluble fraction of meningiomas. (A) Ras 'O' indicates
percentage of GTP that remains associated with p21 ras at zero time, before
incubation. Ras indicates percentage of GTP after an incubation ofp21 ras
for 15 min at 300C, as described in the Patients and methods section.
Incubation in the presence of 1.25 mm dodecyl maltoside (neurofibromin-
specific inhibitor) does not affect the intrinsic GTPase activity of p21 ras. The
addition of 250 jg of soluble fraction of rabbit brain (RB) and meningiomas
nos. 13, 15 and 18 dramatically stimulates intrinsic GTPase activity of p21
ras, which is strongly inhibited by incubation in the presence of maltoside.
The total and maltoside-inhibited GAP activity of meningiomas no. 7 and no.
8 is reduced, indicating diminished GAP activity of neurofibromin. Results
shown are averages of two determinations, with standard deviations less
than 5%. The results shown in (B) are from the dose-response experiment
in which 100-1000 gg of soluble protein from menigiomas were assayed.
Only the results for the 500-jg data point are shown, except for meningioma
no. 6 (1080 jg). In meningiomas nos. 1, 6 and 14, GAP activity was poorly
inhibited by maltoside, indicating reduced GAP activity of neurofibromin in
these tumours
neurofibromin. Incubation with the primary antibodies was done
overnight at 40C. The blots were washed twice in Tris-buffered
saline (TBS) (10 mv Tris-HCl pH 8.0, 150 mm sodium chloride)
with 0.05% Tween 20 for 7 min. The secondary anti-rabbit-
horseradish peroxidase conjugated antibody (Boehringer) was
diluted 1:2000 in blocking buffer and incubated with the blots for
1 h at room temperature. The membranes were washed three times
for 5 min with TBS, 0.05% Tween 20 and washed once for 5 min
with TBS. The proteins were detected using Western blot chemilu-
miniscence reagents (Renaissance, DuPont NEN).
Stripping of the anti-neurofibromin antibodies from membranes
wasperformed for 30 min at 50°C in strippingbuffer(62.5 mmTris-
HCI pH 6.8, 2% SDS, 100 mm 2-mercaptoethanol). The membranes
werethenwashedfourtimes for5 min inTBS, 0.05%Tween 20 and
incubated for I hatroomtemperature inblockingbuffer(1% BSAin
10 mmTris-HCI, pH 7.5, 100mm sodiumchloride, 0.1I% Tween 20).
Mouse monoclonal anti-p120 GAP antibody was obtained from
Zymed and used according to the provided instructions. The
secondary anti-mouse-horseradish peroxidase conjugated antibody
(Boehringer) was diluted 1:5000 in 5% milk blocking buffer and
incubated with the blots for I h at room temperature. Subsequent
steps were performed as described for anti-neurofibromin
immunoblotting.
Mouse monoclonal antibody to actin (Boehringer) was diluted
in the blocking buffer (final concentration 0.5 jig ml-') and incu-
bated at 4°C ovemight. Washing and subsequent steps were done
as described for neurofibromin and pl20 GAP immunoblotting.
Immunoprecipitation of neurofibromin and p120 GAP
To immunoprecipitate neurofibromin from tumour and control
extracts, sodium chloride was added to obtain a final concentration
of 100 mm along with the corresponding antibody. Anti-neuro-
fibromin anti-NFIGRP(N) IgG and anti-NFIGRP(D) IgG were
used at 1 jg persample. The most efficientimmunoprecipitation of
neurofibromin, however, was achieved with anti-NF1(C1) poly-
clonal serum specific for the epitope at the carboxy terminus
(residues 2798-2814) of human neurofibromin. This anti-neuro-
fibromin serum was raised in our laboratory and was successfully
used in immunoblotting and immunoprecipitation experiments
using soluble and particulate fraction extracts of several murine
organs (Golubic et al, 1992). In the present study, 10gl of serum
was used per immunoprecipitation reaction. Two negative controls
were used in the immunoprecipitation experiments. The first was
immunoprecipitation with 10 jl of non-immune rabbit serum. In
the second case anti-neurofibromin antibodies were neutralized by
preincubation with 10-fold (by weight) excess of specific peptide
antigen in PBS for 2 h at room temperature. For p120 GAP
immunoprecipitation, a commercial anti-human p120 GAP poly-
clonal antibody was used (Upstate Biotechnology). This antibody
was raised against GAP fusion protein containing amino acids
171-448 of human GAP and was used at 10 jg per sample. The
incubation with antibodies was done at 4°C ovemight. About 35 jl
ofprotein A Sepharose slurry (50% in bufferA) was added, and the
samples were rotated on the wheel for 40min at 4°C. The beads
with immunoprecipitated neurofibromin were washed twice in
buffer A containing 0.2% Nonidet-P40 and 100 mm sodium
chloride, twice in bufferA containing 100 mm sodium chloride and
once in buffer A. The p120 GAP immunoprecipitates were washed
twice in buffer A containing 0.1% Nonidet-P40 and 75 mm sodium
chloride, twice in buffer A containing 75 mM sodium chloride and
once in buffer A. To reduce the background, the beads were settled
down by gravity, except forthe lastwash whenEppendorfminifuge
was used. The beads were then boiled in I x Laemmli buffer for
2 min and proteins were separated on SDS/PAGE. Protein transfer
and immunoblotting were performed as described above.
GTPase assay with meningioma protein extracts
The p21 ras GTPase stimulatory activity of the S100 fraction of
meningiomas was determinedbyp21 ras immunoprecipitation assay.
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Figure 5 Immunoprecipitation of neurofibromin (grey bars) and p120 GAP
(black bars) from the soluble fraction of meningiomas followed by GTPase
assay. Ras indicates p21 ras 'zero' time (see Figure 4 legend), while N-im,
indicates immunoprecipitation with non-immune serum from human brain
tissue (HB). The numbers indicate each meningioma sample used for
immunoprecipitation (see Table 1)
Briefly, purified bacterially synthesized c-Ha-Ras was incubated for
5 min at 30°C with 1 ,UM [oc-32P]GTP (3000Ci mmol'l; DuPont
NEN) in buffer containing 20 mlv Tris-HCl, pH 7.5, and 1 mM DTT.
GTPase reaction was initiated by addition of magnesium chloride
and the meningioma lysate in 60 pA of reaction buffer (final concen-
trations: 20 mM Tris-HCl, pH 7.5, 1mM DYTT, 5 mM magnesium chlo-
ride, 0.5 mM unlabelled GTP). The final concentration of p21 ras in
the reaction was 30 nM. After incubation at 30°C for 15 mmn, p21 ras
was immunoprecipitated by rat monoclonal antibody Y13-259 and
protein A Sepharose beads coated with rabbit antibody to rat IgG.
Bound nucleotides were released from the immunoprecipitates by
boiling for 2 min in abuffer containing 1 miv EDTA and 0.35% SDS.
The nucleotides were resolved on a polyethyleneimine cellulose
thin-layer chromatography plate with a 1 M potassium phosphate,
pH 3.4, mobile phase. The separated nucleotides were visualized and
their intensity was determined using phosphoimager analysis.
GTPase assay with immunoprecipitated neurofibromin
and p120 GAP
The p21 ras GTPase stimulatory activity of immunoprecipitated
neurofibromin or p120 GAP was determined by p21 ras immuno-
precipitation assay (Golubic et al, 1992). Briefly, protein
A-Sepharose beads with immunoprecipitated neurofibromin or
p120 GAP were incubated for 15 mi at 30°C in the reaction
buffer containing p2u1 ras, as described above. After incubation, rat
monoclonal antibody Y13-259 and protein A-Sepharose beads
coated with rabbit antibody to rat IgG were added to the super-
natant. All subsequent steps were as described above.
RESULTS
Neurofibromin expression in established human
leptomeningeal cell line LTAg2B
The level of neurofibromin expression wasCfrst determined in
established human leptomeningeal cells LTAg2B, from which
meningiomas are thought to develop (Russel and Rubinstein,
1989). We have shown earlier that neurofibromin ispredominantly
expressed and catalytically active in the soluble fraction of the rat
brain (Golubic et al, 1992). Therefore, the soluble fractions of
LTAg2B cells, human braintissue, murine NIH3T3 fibroblast cells
and human astrocytoma CRT cells were immunoblotted by anti-
NFIGRP(N) IgG, which recognizes an epitope localized at the
amino terminus of the human neurofibromin (Figure 1, top). As
expected, a neurofibromin-specific band of about 250 kDa was
detected in human brain tissue. The expression level of neuro-
fibromin in the soluble fraction of leptomeningeal cells LTAg2B
was reduced about twofold in comparison to the brain sample, as
determined by densitometry (not shown). It was however more
than 10-fold higher than in NIH 3T3 fibroblast and astrocytoma
CRT cells. Immunoblotting of the same membrane with an anti-
p120 GAP antibody (after stripping of anti-neurofibromin anti-
body) revealed that the expression level of pl20 GAP differed
little among the samples analysed (Figure 1, bottom).
Neurofibromin expression in meningiomas -
immunoblotting experiments
Neurofibrominexpression levels in meningiomas were determined
by immunoblotting of the soluble fraction of the tumours. The
clinical and histopathological characteristics of 17 sporadic
meningiomas and one NF2-related tumour analysed in this study
are summarized in Table 1. In immunoblotting experiments with
anti-NFlGRP(N) IgG, neurofibromin was detected in the human
brain tissue and in most meningiomas (Figure 2A). In some
tumours (meningiomas nos. 1, 2, 6, 7, 8 and 14), however the
specific 250-kDa band intensity was reduced compared with
human brain tissue and other meningiomas (Figure 2A). Although
immunoblotting with anti-NFlGRP(N) IgG could, theoretically,
detect truncated neurofibromin molecules larger than 70 kDa, no
specific band of size smaller than the 250-kDa band offull-length
neurofibromin was seen in the tumours analysed (not shown).
Neurofibromin was also detected as a 250-kDa band in human
brain tissue and most meningiomas by anti-NFlGRP(D) IgG
(Figure 2B). In this case, the specific band was barely detected in
tumours nos. 1, 2, 6, 7 and 8, while the intensity of the neuro-
fibromin band in other meningiomas was similar to those of
human brain and other meningiomas. In addition to the 250-kDa
band, a faster migrating band of about 200 kDa was detected in
meningiomas but not in human brain tissue (Figure 2B). The iden-
tity of that band and its relationship to neurofibromin is not
known. Immunoblotting experiments in which anti-NFlGRP(D)
IgG was preincubated with homologous peptide suggest that this
band is non-specific (not shown).
The expression of p120 GAP in the soluble fraction of menin-
giomas was analysed using a commercial monoclonal antibody
(Figure 2C). In contrast to the reduced neurofibromin expression
seen in six meningiomas, all tumours expressedp120 GAP at levels
similar or slightly reduced compared with that observed in human
brain tissue. The only exception was tumour no. 14, in which the
intensity of the 120-kDa-specific band was severely reduced
compared with human brain tissue and other meningiomas.
Immunoblot analysis of tumour samples using anti-actin antibody
demonstrates that equal amounts of protein samples were used
(Figure 2D). Detection of the single p120 GAP and actin-specific
band also suggests that non-specific protein degradation of menin-
gioma lysates is not the cause of the reduced neurofibromin levels
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found in the six meningiomas. The staining of the soluble proteins
from tumours with reduced neurofibromin using Coomassie blue
also showed intact high-molecular-weight proteins and no signs of
protein degradation (not shown). The summary of immunoblotting
results is shown in Table 1. Similar results were obtained when
neurofibromin, expressed in the 1% Triton X-100 fraction of the
meningiomas, was analysed by immunoblotting (not shown).
Neurofibromin expression in meningiomas -
immunoprecipitation followed by immunoblotting
experiments
In addition to immunoblotting, the expression level of neurofibro-
min in meningiomas was determined by immunoprecipitation of
neurofibromin from the soluble fraction ofthe tumours followed by
immunoblotting with anti-neurofibromin antibodies. As the avail-
ability of human brain tissue was limited, for immunoprecipitation
experiments a soluble fraction ofrabbit brain was used as a positive
control. Figure 3A shows the results obtained after immunoprecipi-
tation of neurofibromin from 4 mg of soluble fraction of several
meningiomas with anti-NFIGRP(N) IgG or anti-NFIGRP(D)
IgG followed by immunoblotting with anti-NFIGRP(N) IgG.
Immunoblotting of immunoprecipitated neurofibromin from seven
meningiomas revealed a strong 250-kDa-specific band in five
tumours (nos. 9, 10, 11, 12 and 17) (Figure 3A). In contrast to
immunoblotting, anti-NFlGRP(D) IgG was much more efficient in
immunoprecipitation than anti-GRP(N) IgG. Little neurofibromin,
however, was immunoprecipitated even with anti-NFlGRP(D) IgG
from meningiomas no. 7 and no. 8, thus confirming the observation
made by immunoblotting (see Figure 2A and B). Very little, if any,
neurofibromin was immunoprecipitated from meningioma no. 1
(Figure 3B), no. 2 (Figure 3C) and tumours no. 14 and no. 18
(Figure 3D) with anti-neurofibromin anti-NFl(CI) serum specific
for the carboxy terminus ofthe protein.
In contrast to the reduced level of neurofibromin seen in
meningiomas nos. 1, 2, 7, 8, 14 and 18 by immunoprecipitation,
the intensity of immunoprecipitated p120 GAP was similar in all
tumours analysed (see Figure 3B and D for tumours nos. 1, 7 and
18; for other tumours data are not shown). The only exception was
meningioma no. 14, in which p120 GAP was significantly reduced
(Figure 3D).
In addition to neurofibromin, in some meningiomas (see
tumours no. 7 and no.11 in Figure 3A; no. 13 and no. 18 in Figure
3D) a faster migrating band of about 200 kDa was also immuno-
precipitated with both antibodies. The relationship of that protein
to neurofibromin, however, is unknown. The presence of this band
did not correlate with the reduction of neurofibromin, as it is
detected in meningiomas no. 11 and no. 13, which expressed
normal levels of neurofibromin. No other specific band of smaller
size was detected by immunoprecipitation in any meningioma.
GTPase-activating protein (GAP) activity of
neurofibromin from meningioma lysates
Atpresent, stimulation ofp21 ras GTPase activity is the only known
function ofneurofibromin (Xu et al, 1990; Golubic et al, 1992), and
it was therefore used as another measure ofneurofibromin levels in
meningiomas. The GAP activity ofneurofibromin from the soluble
fraction ofmeningiomas was determined by p21 ras GTPase assay.
A detergent dodecyl maltoside potently inhibits GAP activity of
neurofibromin but not that of p120 GAP (Bollag and McCormick,
1991) and was used at a concentration of 1.25 mM to determine the
contribution of neurofibromin to the total GAP activity of menin-
gioma lysates. The total GAP activity minus maltoside-insensitive
activity is due to neurofibromin. The total and dodecyl maltoside-
susceptible GAP activity of the soluble fraction of 18 meningiomas
(tumours no. 1 through to no. 18) and rabbit brain as a positive
control were determined (Figure 4A and B).
The GTPase stimulatory activity of tumours nos. 2, 5, 9, 11, 13,
15 and 18 contained maltoside-susceptible GAP activity similar to
that seen in brain tissue (Figure 4A and B). In five meningiomas
(nos. 1, 6, 7, 8 and 14), GAP activity was only weakly susceptible
to inhibition by maltoside (Figure 4A and B) and therefore
contained little GTPase-stimulatory activity upon p21 ras that
could be attributed to neurofibromin.
Although results of this functional analysis of neurofibromin
mostly correlated well with the results ofthe previous experiments
(exceptions were tumours no. 2 and no. 18), their interpretation is
complicated by recent identification of other p21 ras-specific GAP
proteins in the brain tissue (Maekawa et al, 1994; Weisbach et al,
1994; Baba et al, 1995). At present, it is not known whether these
proteins are expressed in meningiomas and whether their GAP
activity is susceptible to inhibition by maltoside.
GAP activity of immunoprecipitated neurofibromin
To eliminate the possibility that other p21 ras-specific GAP mole-
cules (Maekawa et al, 1994; Weisbach et al, 1994; Baba et al,
1995), besides neurofibromin and p120 GAP, contribute to the total
and maltoside-sensitive GAP activity of meningioma lysates,
neurofibromin and p120 GAP were immunoprecipitated from the
soluble fraction of meningiomas, and the GAP activity of immuno-
precipitated proteins was determined in p21 ras GTPase assay.
Neurofibromin was immunoprecipitated from 4 mg of the
soluble fraction from 12 meningiomas with the anti-NFI(CI)
polyclonal antibody specific for the epitope at the carboxy
terminus of human neurofibromin. The GAP activity of immuno-
precipitated neurofibromin was high in meningiomas that had
previously shown good maltoside-susceptible GAP activity
(tumours nos. 9-13 and 15-17). The average GAP activity of
immunoprecipitated neurofibromin in these meningiomas was
83% (range 75-97%; standard deviation 7.5) of the activity
detected in neurofibromin immunoprecipitated from the soluble
fraction of human brain (Figure 5 and Table 1). In contrast, GAP
activity of immunoprecipitated neurofibromin from meningiomas
nos. 1, 7, 8, 14 and 18 was substantially reduced (Figure 5 and
Table 1). Immunoprecipitated neurofibromin from meningiomas
nos. 1, 8 and 14 had only 16%, 19% and 27% of GAP activity of
neurofibromin from human brain tissue respectively (Table 1). The
reduction ofneurofibromin's GAP activity from tumours no. 7 and
no. 18 was less severe (42% and 38% respectively). Results similar
to those in Figure 5 and Table 1 were obtained when GAP activity
of neurofibromin was determined after its immunoprecipitation
from 2 mg of soluble protein from meningiomas (not shown).
Immunoprecipitation with anti-p120 GAP antibody was also
performed as a control. In contrast to the substantial reduction of
GAP activity of immunoprecipitated neurofibromin from menin-
giomas nos. 1, 7, 8, 14 and 18, the p120 GAP GTPase stimulatory
activity was either unchanged or slightly reduced in these tumours
compared with other meningiomas with good neurofibromin
expression (see Figure 5 and Table 1). To better estimate the
degree ofneurofibromin reduction in these meningiomas, the ratio
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between the GAP activity of neurofibromin and p120 GAP was
calculated (see Table 1). Compared with the neurofibromin-pl20
GAP ratio defined as 1.00 in human brain tissue, three tumours
(nos. 7, 14 and 18) had a ratio ofabout 0.6. Tumours no.1 and no.
8 had an even smaller neurofibromin-p120 GAP ratio of0.18 and
0.36 respectively. All other meningiomas tested had an average
ratio of 1.15 (range 0.99-1.27). These experiments conclusively
confirmed the conspicuous reduction of neurofibromin and
its GAP activity in meningiomas nos. 1, 7, 8 and 14 observed
throughout this study.
DISCUSSION
This study resulted in several novel observations concerning the
role that neurofibromin might play in meningioma tumorigenesis.
After extensive analysis using four different methods, we show for
the first time that neurofibromin is expressed at high levels in
leptomeningeal cells and in sporadic meningiomas, their tumour
derivatives. Furthermore, reduced expression and consequently
diminished GAP activity of neurofibromin were found in about
28% of the tumours analysed.
Neurofibromin expression in the adult nervous system was found
by immunostaining of tissue sections limited to neurons, oligoden-
drocytes and non-myelinating Schwann cells (Daston et al, 1992).
This study provides evidence that neurofibromin is also highly
expressed in the established human leptomeningeal cell line.
Although LTAg2B cells might differ from native leptomeningeal
cells, at least by morphology and expression of tissue markers,
they are indistinguishable from arachnoid cells of leptomeninges
(Murphy et al, 1991). As determined by immunoblotting, these cells
abundantly expressed full-length neurofibromin at levels 10-fold
higher than murine NIH 3T3 fibroblast and human astrocytoma cell
line CRT. In contrast, the expression level of p120 GAP was found
to be similar among these cells. The high expression level of
neurofibromin in the leptomeningeal cell line suggests that functions
of neurofibromin in these cells could be physiologically important,
as already shown for Schwann cells (Basu et al, 1992; DeClue et al,
1992; Takahashi et al, 1995) and neurons (Vogel et al, 1995).
Based on results obtained by immunoprecipitation and immuno-
blotting experiments, we concluded that 11 out of 18 meningiomas
expressed neurofibromin at levels similar or slightly reduced
compared with human brain tissue. The results of the GTPase
assay with the soluble fraction of meninigiomas and neurofibro-
min immunoprecipitated from these tumours were compatible
with the neurofibromin expression data (Table 1).
In five tumours (meningioma nos. 1, 6, 7, 8 and 14), the expres-
sion levels of neurofibromin and neurofibromin's GAP activity
were reduced in comparison to other meningiomas. Reduced
expression of neurofibromin was also found in meningioma no. 2
by immunoblotting with amino and carboxy terminus-specific
antibodies (Figure 2) and immunoprecipitation with the antibody
recognizing an epitope at the carboxy terminus of the molecule
(Figure 3C). In tumour no. 18, reduced neurofibromin was detected
only by immunoprecipitation with antibody directed against the
carboxy terminus of the protein (Figure 3D and Table 1).
Consequently, GAP activity of immunoprecipitated neurofibromin
from tumour no. 18 was reduced (meningioma no. 2 was not
analysed using this assay) (Figure 5 and Table 1). Examination of
the maltoside-susceptible GAP activity of these two meningiomas,
however, suggested that neurofibromin is catalytically active at
levels similar to other meningiomas with normal neurofibromin
expression (Figure 4). The discrepancy in tumour no. 18 could be
explained by the presence of an altered epitope site at the carboxy
terminus of neurofibromin that prevented efficient immunoprecipi-
tation. The conflicting finding of the obvious reduction of neuro-
fibromin expression and the presence of maltoside-susceptible
activity in meningioma no. 2 can be explained by the presence of
maltoside-susceptible GAP activity that is distinct from neuro-
fibromin. It is not known, however, whether other p21 ras-specific
GAPs are susceptible to inhibition by maltoside (Maekawa et al,
1994; Weisbach et al, 1994).
In contrast to alterations found in neurofibromin, the expression
levels and catalytic activity of the other p21 ras-specific GTPase
stimulatory protein, p120 GAP, were similar in all meningiomas
except in malignant tumour no. 14. In this tumour, both neuro-
fibromin and p120 GAP were reduced. The reduction of GAP
activity of neurofibromin, however, was more severe than that of
p120 GAP (Table 1).
No association between the age of meningioma detection and
neurofibromin status was found. There was also no clear correla-
tion between tumour location and reduced expression of neuro-
fibromin. Reduced neurofibromin expression and its GAP activity
were found in all histological types of sporadic tumours examined,
except in a single fibroblastic meningioma. This occurred in
meningiomas of meningotheliomatous (four out of nine, 44%),
transitional (two out offive, 40%) and malignant (one out ofthree,
33%) histological types. The reduced neurofibromin expression
and GAP function was therefore not associated with any particular
histological type. Surprisingly, a meningioma derived from an
NF2 patient had a severely reduced expression level and GAP
activity of neurofibromin. As expected, the analysis of protein
extracts from that tumour indicated an absence of schwan-
nomin/merlin (not shown).
Recently we found that frequency of schwannomin/merlin
reduction in meningotheliomatous meningiomas was significantly
lower than in other histological tumour types (Lee et al, 1997).
This suggests that development of meningotheliomatous menin-
giomas is probably linked with alterations in other oncogenes or
tumour-suppressor genes. Interestingly, three of four meningothe-
liomatous tumours with altered neurofibromin (nos. 6, 8 and 18)
expressed normal levels of schwannomin/merlin (Lee et al, 1997).
One interesting possibility is that neurofibromin and schwan-
nomin/merlin control similar or interacting biochemical intra-
cellular pathways and that disruption of either one contributes to
meningioma development.
Both neurofibromin and schwannomin/merlin might be involved
in signalling through the p21 ras pathway. Recent study suggests
that the tumour-suppressor activity of schwannomin/merlin could
be mediated through its anti-p21 ras function (Tikoo et al, 1994).
Neurofibromin is considered to act as a negative regulator of p21
ras (Lowy and Willumsen, 1993) and as its effector (Moodie et al,
1995). Reduced neurofibromin expression in meningiomas could
lead to changes in both functions because five meningiomas with
reduced catalytic activity of neurofibromin expressed little of the
full-length protein. No meningioma with a normal neurofibromin
expression level and impaired GAP activity was found, suggesting
that GRD of neurofibromin in these tumours was functionally
intact. Therefore, it is likely that the inactivating mutations
described in GRD of neurofibromin in other tumour types (Li et al,
1992) are absent or are rare in meningiomas.
The lack ofknowledge about p21 ras expression and alterations
in meningiomas further obscures the role ofneurofibromin in p21
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ras signalling in meningiomas (Salgaller et al, 1990; Arvanitis
et al, 1991). More data indirectly suggest p21 ras importance.
The strong inappropriate expression (compared with normal
leptomeningeal cells) of polypeptide growth factors and their
receptors on the same population ofmeningioma cells suggests the
important possibility of autocrine or paracrine functions for these
factors (Todo et al, 1996). Because extracellular growth factors
found in meningiomas act through protein tyrosine kinase recep-
tors and activate p21 ras, the reduced expression of neurofibromin
and the consequent decrease in both the negative regulation ofp21
ras and/or its effector activity might be of importance in the
tumorigenesis of meningiomas. If neurofibromin is the major
regulator ofp21 ras in leptomeningeal cells or meningiomas, as in
the Schwann cells (Basu et al, 1992; DeClue et al, 1992), then the
diminished GTPase stimulatory activity of neurofibromin would
result in an increase of the proportion of p21 ras bound to GTP.
Neurofibromin, however, does not stimulate GTPase activity of
oncogenically activated p21 ras (Trahey and McCormick, 1987). It
remains to be demonstrated whether oncogenic mutations in p21
ras occur in meningiomas and whether proliferation of menin-
giomas is dependent on the presence of the functional p21 ras.
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